CD38
CD38 (CD38 molecule, cADPR1) is a multifunctional type II transmembrane glycoprotein that synthesises and hydrolyses cyclic ADP-ribose, a calcium-mobilising messenger. It also acts as a receptor for CD31 and was previously named CD38 antigen (p45). Browse Assay Genie's current range of CD38 research reagents below, or read on for the biology behind the target.
CD38 is a multifunctional transmembrane glycoprotein that combines enzymatic, receptor and adhesion activities. As an enzyme it synthesises cyclic ADP-ribose (cADPR), a second messenger for glucose-induced insulin secretion, and also has cADPR hydrolase activity. It additionally makes the calcium mobilizer nicotinate-adenine dinucleotide phosphate (NAADP+) from 2'-phospho-cADPR and nicotinic acid, or from NADP+ and nicotinic acid. At both pH 5.0 and pH 7.4 it preferentially converts 2'-phospho-cADPR into NAADP+, while NADP+ is preferentially cleaved to cADPR and ADPRP.
CD38 also functions as a receptor that binds CD31 on endothelial cells, promoting lymphocyte activation, proliferation and migration across the endothelial barrier. It is involved in regulating dendritic cell functions acquired at the mature stage, including CCL21-driven migration, survival and Th1-polarising activity. In lamina propria T lymphocytes, CD38/CD31 interactions initiate a multistep signalling pathway that activates LCK and LAT, followed by cytokine release.
The CD38 gene encodes a non-lineage-restricted type II transmembrane glycoprotein with an N-terminal cytoplasmic tail, a single membrane-spanning domain and a C-terminal extracellular region carrying four N-glycosylation sites. Crystal structure analysis shows that the functional molecule is a dimer, with the catalytic site in its central portion. Release of soluble protein and internalisation of the membrane-bound form point to both extracellular and intracellular roles. CD38 belongs to the ADP-ribosyl cyclase family, is used as a prognostic marker in chronic lymphocytic leukaemia, and alternative splicing produces multiple transcript variants.
CD38 produces cADPR and NAADP+, two calcium-mobilising messengers, making it a central enzyme for studying intracellular calcium signalling.
CD38 synthesises cADPR, a second messenger for glucose-induced insulin secretion, linking the enzyme to metabolic signalling studies.
Binding of CD31 on endothelial cells by CD38 promotes lymphocyte activation, proliferation and migration across the endothelial barrier.
CD38 is used as a prognostic marker for patients with chronic lymphocytic leukaemia, supporting haematological malignancy research.
CD38 is a cell-surface glycoprotein with enzymatic and receptor roles. It synthesises and hydrolyses cyclic ADP-ribose, makes the calcium mobilizer NAADP+, and binds CD31 on endothelial cells to promote lymphocyte activation, proliferation and migration. It also supports dendritic cell functions such as CCL21-driven migration.
The HGNC name is CD38 molecule, and the UniProt name is ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1. The alias cADPR1 and the earlier name CD38 antigen (p45) are also used. Alternative splicing of the gene results in multiple transcript variants.
Orthologues of the human gene are annotated in mouse and rat, both named Cd38. In disease, CD38 is used as a prognostic marker for patients with chronic lymphocytic leukaemia. Check the datasheet of any product for its validated reactivity.
Other CD molecules, including lymphocyte, myeloid and plasma cell surface markers, with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P28907; product specifications from Assay Genie datasheets.